Hepatitis C vaccine

Source: Wikipedia, the free encyclopedia.

Hepatitis C vaccine
Vaccine description
TargetHepatitis C
Identifiers
CAS Number
ChemSpider
  • none

A hepatitis C vaccine, a vaccine capable of protecting against the hepatitis C virus (HCV), is not yet available. Although vaccines exist for hepatitis A and hepatitis B, development of an HCV vaccine has presented challenges.[1] No vaccine is currently available, but several vaccines are currently under development.[2][3]

Most vaccines work through inducing an antibody response that targets the outer surfaces of viruses. However, the HCV virus is highly variable among strains and rapidly mutating, making an effective vaccine very difficult.[4]

Another strategy which is different from a conventional vaccine is to induce the

adenoviral vectors that contain large parts of the HCV genome itself, to induce a T cell immune response against HCV.[citation needed] Most of the work to develop a T cell vaccine has been done against a particular genotype.[citation needed] There are six different genotypes which reflect differences in the structure of the virus. The first approved vaccine will likely only target genotypes 1a and 1b, which account for over 60% of chronic HCV infections worldwide.[5]
Likely, vaccines following the first approved vaccine will address other genotypes by prevalence.

VLP-based HCV vaccines are also subject of intensive research.[6]

Since 2014, well-tolerated and extremely effective direct‐acting antiviral agents (DAAs) have been available which allows eradication of the disease in 8–12 weeks in most patients.[7] While this has changed treatment options drastically for patients with HCV, it does not replace a vaccine that would prevent people from ever getting infected with the virus and will likely not be sufficient to eradicate HCV completely.[7]

Specific vaccines

As of 2020,

Phase I clinical trial.[9]

The major histocompatibility complex class II-associated invariant chain (CD74)—fused with a viral vector to a conserved region of the HCV genome—has been tested as an adjuvant for an HCV vaccine in a cohort of 17 healthy human volunteers. This experimental vaccine was well-tolerated, and those who received the adjuvanted vaccine had stronger anti-HCV immune responses (enhanced magnitude, breadth and proliferative capacity of anti-HCV-specific T helper cells) compared with volunteers who received the vaccine that lacked this adjuvant.[10]

References

  1. PMID 10359539
    .
  2. PMID 18501853
    .
  3. ^ "Hepatitis C Questions and Answers for the Public". Centers for Disease Control and Prevention. 10 September 2019. Retrieved 20 April 2023.
  4. ^ "Scripps Research Institute Scientists Achieve Most Detailed Picture Ever of Key Part of Hepatitis C Virus" (Press release). Scripps Research Institute. 28 November 2013. Retrieved 6 December 2013.
  5. ^ "The hepatitis C virus". WHO. Archived from the original on 4 October 2013. Retrieved 1 October 2013.
  6. PMID 29163442
    .
  7. ^
    PMID 30472772
    .
  8. PMID 25424943
    .
  9. ^ Clinical trial number NCT02772003 for "DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection" at ClinicalTrials.gov
  10. S2CID 219722045
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hepatitis_C_vaccine&oldid=1193726178"